

# Daniel Matthias Aebersold

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6937904/publications.pdf>

Version: 2024-02-01

176  
papers

4,519  
citations

117453

34  
h-index

133063

59  
g-index

187  
all docs

187  
docs citations

187  
times ranked

6692  
citing authors

#	ARTICLE	IF	CITATIONS
1	Human papillomavirus positive squamous cell carcinoma of the oropharynx. <i>Cancer</i> , 2001, 92, 805-813.	2.0	422
2	Hyperthermia-related clinical trials on cancer treatment within the ClinicalTrials.gov registry. <i>International Journal of Hyperthermia</i> , 2015, 31, 609-614.	1.1	173
3	The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants. <i>Oncogene</i> , 2004, 23, 5387-5393.	2.6	170
4	Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial. <i>Lancet Oncology</i> , The, 2015, 16, 1651-1658.	5.1	170
5	Abiraterone in "High" and "Low-risk" Metastatic Hormone-sensitive Prostate Cancer. <i>European Urology</i> , 2019, 76, 719-728.	0.9	142
6	The chemokine CCL20 and its receptor CCR6 in human malignancy with focus on colorectal cancer. <i>International Journal of Cancer</i> , 2009, 125, 741-745.	2.3	127
7	Significant correlation of hypoxia-inducible factor-1 $\alpha$ with treatment outcome in cervical cancer treated with radical radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003, 56, 494-501.	0.4	117
8	Hypoxia-inducible factor 1 alpha in high-risk breast cancer: an independent prognostic parameter?. <i>Breast Cancer Research</i> , 2004, 6, R191-8.	2.2	106
9	Acute Toxicity and Quality of Life After Dose-Intensified Salvage Radiation Therapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: First Results of the Randomized Trial SAKK 09/10. <i>Journal of Clinical Oncology</i> , 2015, 33, 4158-4166.	0.8	99
10	Current status and perspectives of interventional clinical trials for glioblastoma " analysis of ClinicalTrials.gov. <i>Radiation Oncology</i> , 2017, 12, 1.	1.2	87
11	Involvement of the hepatocyte growth factor/scatter factor receptor c-met and of Bcl-xL in the resistance of oropharyngeal cancer to ionizing radiation. <i>International Journal of Cancer</i> , 2001, 96, 41-54.	2.3	82
12	Toxicity and early treatment outcomes in low- and intermediate-risk prostate cancer managed by high-dose-rate brachytherapy as a monotherapy. <i>Brachytherapy</i> , 2009, 8, 45-51.	0.2	72
13	The Essential Role of Radiotherapy in the Treatment of Merkel Cell Carcinoma: A Study From the Rare Cancer Network. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, e583-e591.	0.4	67
14	Dose-intensified Versus Conventional-dose Salvage Radiotherapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: The SAKK 09/10 Randomized Phase 3 Trial. <i>European Urology</i> , 2021, 80, 306-315.	0.9	64
15	Protocol for serum exosomal miRNAs analysis in prostate cancer patients treated with radiotherapy. <i>Journal of Translational Medicine</i> , 2018, 16, 223.	1.8	60
16	Prevalence and clinical impact of Met Y1253D-activating point mutation in radiotherapy-treated squamous cell cancer of the oropharynx. <i>Oncogene</i> , 2003, 22, 8519-8523.	2.6	59
17	Extracellular Signal-Regulated Kinase 1c (ERK1c), a Novel 42-Kilodalton ERK, Demonstrates Unique Modes of Regulation, Localization, and Function. <i>Molecular and Cellular Biology</i> , 2004, 24, 10000-10015.	1.1	58
18	Impact of weight loss on survival after chemoradiation for locally advanced head and neck Cancer: secondary results of a randomized phase III trial (SAKK 10/94). <i>Radiation Oncology</i> , 2015, 10, 21.	1.2	58

#	ARTICLE	IF	CITATIONS
19	Combining Enzalutamide with Abiraterone, Prednisone, and Androgen Deprivation Therapy in the STAMPEDE Trial. <i>European Urology</i> , 2014, 66, 799-802.	0.9	56
20	Exosomes and Exosomal MicroRNAs in Prostate Cancer Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 982-995.	0.4	56
21	MET inhibition in tumor cells by PHA665752 impairs homologous recombination repair of DNA double strand breaks. <i>International Journal of Cancer</i> , 2012, 130, 728-734.	2.3	49
22	Intratumoral microvessel density predicts local treatment failure of radically irradiated squamous cell cancer of the oropharynx. <i>International Journal of Radiation Oncology Biology Physics</i> , 2000, 48, 17-25.	0.4	48
23	Quantitative Analysis of Extracapsular Extension of Metastatic Lymph Nodes and its Significance in Radiotherapy Planning in Head and Neck Squamous Cell Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 76, 1127-1132.	0.4	48
24	Gefitinib in Combination With Irradiation With or Without Cisplatin in Patients With Inoperable Stage III Non-Small Cell Lung Cancer: A Phase I Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 80, 126-132.	0.4	46
25	Relation of baseline neutrophil-to-lymphocyte ratio to survival and toxicity in head and neck cancer patients treated with (chemo-) radiation. <i>Radiation Oncology</i> , 2018, 13, 216.	1.2	46
26	Altered Regulation of ERK1b by MEK1 and PTP-SL and Modified Elk1 Phosphorylation by ERK1b Are Caused by Abrogation of the Regulatory C-terminal Sequence of ERKs. <i>Journal of Biological Chemistry</i> , 2001, 276, 35280-35289.	1.6	45
27	Clinically significant bleeding in incurable cancer patients: effectiveness of hemostatic radiotherapy. <i>Radiation Oncology</i> , 2012, 7, 132.	1.2	45
28	MET Inhibition Results in DNA Breaks and Synergistically Sensitizes Tumor Cells to DNA-Damaging Agents Potentially by Breaching a Damage-Induced Checkpoint Arrest. <i>Genes and Cancer</i> , 2010, 1, 1053-1062.	0.6	42
29	High Dose-Rate Versus Low Dose-Rate Brachytherapy for Lip Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 83, 1205-1212.	0.4	41
30	Hypofractionated radiotherapy for localized prostate cancer. <i>Strahlentherapie Und Onkologie</i> , 2017, 193, 1-12.	1.0	40
31	MET targeting: time for a rematch. <i>Oncogene</i> , 2020, 39, 2845-2862.	2.6	40
32	IMRT with 18FDG-PETCT based simultaneous integrated boost for treatment of nodal positive cervical cancer. <i>Radiation Oncology</i> , 2014, 9, 83.	1.2	38
33	Fully automated brain resection cavity delineation for radiation target volume definition in glioblastoma patients using deep learning. <i>Radiation Oncology</i> , 2020, 15, 100.	1.2	37
34	MET Y1253D-activating point mutation and development of distant metastasis in advanced head and neck cancers. <i>Clinical and Experimental Metastasis</i> , 2009, 26, 809-815.	1.7	36
35	The relevance of tyrosine kinase inhibitors for global metabolic pathways in cancer. <i>Molecular Cancer</i> , 2018, 17, 27.	7.9	36
36	Concomitant Cisplatin and Hyperfractionated Radiotherapy in Locally Advanced Head and Neck Cancer: 10-Year Follow-Up of a Randomized Phase III Trial (SAKK 10/94). <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, 524-531.	0.4	34

#	ARTICLE	IF	CITATIONS
37	The Molecular Crosstalk between the MET Receptor Tyrosine Kinase and the DNA Damage Response—Biological and Clinical Aspects. <i>Cancers</i> , 2014, 6, 1-27.	1.7	32
38	Protective autophagy is involved in resistance towards MET inhibitors in human gastric adenocarcinoma cells. <i>Biochemical and Biophysical Research Communications</i> , 2013, 431, 264-269.	1.0	30
39	Outcome and patterns of failure after postoperative intensity modulated radiotherapy for locally advanced or high-risk oral cavity squamous cell carcinoma. <i>Radiation Oncology</i> , 2012, 7, 175.	1.2	29
40	Assessment of patient setup errors in IGRT in combination with a six degrees of freedom couch. <i>Zeitschrift Fur Medizinische Physik</i> , 2014, 24, 112-122.	0.6	29
41	Palliative Interstitial HDR Brachytherapy for Recurrent Rectal Cancer. <i>Strahlentherapie Und Onkologie</i> , 2003, 179, 458-463.	1.0	28
42	Prostate radiotherapy for men with metastatic disease: a new comparison in the <sc>S</sc>ystemic <sc>T</sc>herapy in <sc>A</sc>dvancing or <sc>M</sc>etastatic <sc>P</sc>rostate <sc>C</sc>ancer: <sc>E</sc>valuation of <sc>D</sc>rug <sc>E</sc>fficacy (<sc>STAMPEDE</sc>) trial. <i>BJU International</i> , 2013, 111, 697-699.	1.3	28
43	Late toxicity and five year outcomes after high-dose-rate brachytherapy as a monotherapy for localized prostate cancer. <i>Radiation Oncology</i> , 2014, 9, 122.	1.2	28
44	Acute and late toxicity in prostate cancer patients treated by dose escalated intensity modulated radiation therapy and organ tracking. <i>Radiation Oncology</i> , 2008, 3, 35.	1.2	27
45	The Novel ATP-Competitive Inhibitor of the MET Hepatocyte Growth Factor Receptor EMD1214063 Displays Inhibitory Activity against Selected MET-Mutated Variants. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 2415-2424.	1.9	27
46	Depletion of FOXM1 via MET Targeting Underlies Establishment of a DNA Damage—Induced Senescence Program in Gastric Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 5322-5336.	3.2	27
47	DNA-PK in human malignant disorders: Mechanisms and implications for pharmacological interventions. , 2020, 215, 107617.		27
48	Expression of transforming growth factor- $\beta$ , epidermal growth factor receptor and platelet-derived growth factors A and B in oropharyngeal cancers treated by curative radiation therapy. <i>Radiotherapy and Oncology</i> , 2002, 63, 275-283.	0.3	26
49	Predictors of severe late radiotherapy-related toxicity after hyperfractionated radiotherapy with or without concomitant cisplatin in locally advanced head and neck cancer. Secondary retrospective analysis of a randomized phase III trial (SAKK 10/94). <i>Radiotherapy and Oncology</i> , 2012, 104, 213-218.	0.3	26
50	Use of androgen deprivation and salvage radiation therapy for patients with prostate cancer and biochemical recurrence after prostatectomy. <i>Strahlentherapie Und Onkologie</i> , 2018, 194, 619-626.	1.0	26
51	Part 1: Optimization and evaluation of dynamic trajectory radiotherapy. <i>Medical Physics</i> , 2018, 45, 4201-4212.	1.6	26
52	A national survey on radiation oncology patterns of practice in Switzerland during the COVID-19 pandemic: Present changes and future perspectives. <i>Radiotherapy and Oncology</i> , 2020, 150, 1-3.	0.3	26
53	Incidence of Small Lymph Node Metastases With Evidence of Extracapsular Extension: Clinical Implications in Patients With Head and Neck Squamous Cell Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 78, 1366-1372.	0.4	24
54	Implications of intraglandular lymph node metastases in primary carcinomas of the parotid gland. <i>Laryngoscope</i> , 2015, 125, 2099-2106.	1.1	24

#	ARTICLE	IF	CITATIONS
55	KRAS and HRAS mutations confer resistance to MET targeting in preclinical models of MET-expressing tumor cells. <i>Molecular Oncology</i> , 2015, 9, 1434-1446.	2.1	24
56	Coupling of Mutated Met Variants to DNA Repair via Abl and Rad51. <i>Cancer Research</i> , 2008, 68, 5769-5777.	0.4	23
57	Use of EORTC Target Definition Guidelines for Dose-Intensified Salvage Radiation Therapy for Recurrent Prostate Cancer: Results of the Quality Assurance Program of the Randomized Trial SAKK 09/10. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 87, 534-541.	0.4	23
58	Dose escalated intensity modulated radiotherapy in the treatment of cervical cancer. <i>Radiation Oncology</i> , 2015, 10, 240.	1.2	23
59	Interplay between receptor tyrosine kinases and hypoxia signaling in cancer. <i>International Journal of Biochemistry and Cell Biology</i> , 2015, 62, 101-114.	1.2	23
60	T1-glottic cancer treated with radiotherapy and/or surgery. <i>Strahlentherapie Und Onkologie</i> , 2017, 193, 995-1004.	1.0	23
61	Impact of Early Prophylactic Cranial Irradiation With Hippocampal Avoidance on Neurocognitive Function in Patients With Limited Disease Small Cell Lung Cancer. A Multicenter Phase 2 Trial (SAKK) Tj ETQq1 1 0.784314 rgeBT /Over	0.3	22
62	Daily organ tracking in intensity-modulated radiotherapy of prostate cancer using an electronic portal imaging device with a dose saving acquisition mode. <i>Radiotherapy and Oncology</i> , 2006, 79, 101-108.	0.3	22
63	The Effectiveness and Safety of Proton Radiation Therapy for Indications of the Eye. <i>Strahlentherapie Und Onkologie</i> , 2009, 185, 211-221.	1.0	22
64	Association of urethral toxicity with dose exposure in combined high-dose-rate brachytherapy and intensity-modulated radiation therapy in intermediate- and high-risk prostate cancer. <i>Radiotherapy and Oncology</i> , 2009, 91, 237-242.	0.3	22
65	Guidance of treatment decisions in risk-adapted primary radiotherapy for prostate cancer using multiparametric magnetic resonance imaging: a single center experience. <i>Radiation Oncology</i> , 2015, 10, 47.	1.2	22
66	Comprehensive Genomic Profiling of Patient-matched Head and Neck Cancer Cells: A Preclinical Pipeline for Metastatic and Recurrent Disease. <i>Molecular Cancer Research</i> , 2018, 16, 1912-1926.	1.5	22
67	High-Dose (80 Gy) Intensity-Modulated Radiation Therapy with Daily Image-Guidance as Primary treatment for Localized Prostate Cancer. <i>Strahlentherapie Und Onkologie</i> , 2010, 186, 687-692.	1.0	21
68	Differential inhibition sensitivities of MET mutants to the small molecule inhibitor SU11274. <i>Cancer Letters</i> , 2010, 289, 228-236.	3.2	21
69	Up-front neck dissection followed by definitive (chemo)-radiotherapy in head and neck squamous cell carcinoma: Rationale, complications, toxicity rates, and oncological outcomes – A systematic review. <i>Radiotherapy and Oncology</i> , 2016, 119, 185-193.	0.3	21
70	Targeting of the MET receptor tyrosine kinase by small molecule inhibitors leads to MET accumulation by impairing the receptor downregulation. <i>FEBS Letters</i> , 2014, 588, 653-658.	1.3	20
71	Prognostic value of matrix metalloproteinases in oral squamous cell carcinoma. <i>Biotechnology and Biotechnological Equipment</i> , 2014, 28, 1138-1149.	0.5	19
72	Beamlet based direct aperture optimization for MERT using a photon MLC. <i>Medical Physics</i> , 2014, 41, 1217-1211.	1.6	19

#	ARTICLE	IF	CITATIONS
73	Identification of a MET-eIF4G1 translational regulation axis that controls HIF-1 $\alpha$ levels under hypoxia. <i>Oncogene</i> , 2018, 37, 4181-4196.	2.6	19
74	Impact of dose intensified salvage radiation therapy on urinary continence recovery after radical prostatectomy: Results of the randomized trial SAKK 09/10. <i>Radiotherapy and Oncology</i> , 2018, 126, 257-262.	0.3	19
75	PIK3CA hotspot mutations differentially impact responses to MET targeting in MET-driven and non-driven preclinical cancer models. <i>Molecular Cancer</i> , 2017, 16, 93.	7.9	18
76	Outcome of proximal esophageal cancer after definitive combined chemo-radiation: a Swiss multicenter retrospective study. <i>Radiation Oncology</i> , 2017, 12, 97.	1.2	18
77	Oncogene addiction as a foundation of targeted cancer therapy: The paradigm of the MET receptor tyrosine kinase. <i>Cancer Letters</i> , 2019, 443, 189-202.	3.2	18
78	Statistical Modeling of the Eye for Multimodal Treatment Planning for External Beam Radiation Therapy of Intraocular Tumors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 84, e541-e547.	0.4	17
79	Disease Control With Delayed Salvage Radiotherapy for Macroscopic Local Recurrence Following Radical Prostatectomy. <i>Frontiers in Oncology</i> , 2019, 9, 12.	1.3	17
80	Biological, diagnostic and therapeutic relevance of the MET receptor signaling in head and neck cancer. , 2014, 143, 337-349.		16
81	Applicability and Dosimetric Impact of Ultrasound-Based Preplanning in High-Dose-Rate Brachytherapy of Prostate Cancer. <i>Strahlentherapie Und Onkologie</i> , 2004, 180, 351-357.	1.0	15
82	Carcinoma of the Oropharynx: Local Failure as the Decisive Parameter for Distant Metastases and Survival. <i>Strahlentherapie Und Onkologie</i> , 2000, 176, 16-21.	1.0	14
83	Forward treatment planning for modulated electron radiotherapy (MERT) employing Monte Carlo methods. <i>Medical Physics</i> , 2014, 41, 031712.	1.6	14
84	Outcomes in Advanced Head and Neck Cancer Treated with Up-front Neck Dissection prior to (Chemo)Radiotherapy. <i>Otolaryngology - Head and Neck Surgery</i> , 2016, 154, 300-308.	1.1	14
85	Whole-ventricular irradiation for intracranial germ cell tumors: Dosimetric comparison of pencil beam scanned protons, intensity-modulated radiotherapy and volumetric-modulated arc therapy. <i>Clinical and Translational Radiation Oncology</i> , 2019, 15, 53-61.	0.9	14
86	Role of combined radiation and androgen deprivation therapy in intermediate-risk prostate cancer. <i>Strahlentherapie Und Onkologie</i> , 2020, 196, 109-116.	1.0	14
87	Urethral toxicity vs. cancer control – Lessons to be learned from high-dose rate brachytherapy combined with intensity-modulated radiation therapy in intermediate- and high-risk prostate cancer. <i>Brachytherapy</i> , 2011, 10, 286-294.	0.2	13
88	Haemoglobin and creatinine values as prognostic factors for outcome of concurrent radiochemotherapy in locally advanced head and neck cancers. <i>Strahlentherapie Und Onkologie</i> , 2016, 192, 552-560.	1.0	13
89	Importance and outcome relevance of central pathology review in prostatectomy specimens: data from the SAKK 09/10 randomized trial on prostate cancer. <i>BJU International</i> , 2017, 120, E45-E51.	1.3	13
90	Senescence as biologic endpoint following pharmacological targeting of receptor tyrosine kinases in cancer. <i>Biochemical Pharmacology</i> , 2017, 126, 1-12.	2.0	13

#	ARTICLE	IF	CITATIONS
91	Prospective Study of Exclusive Strontium-90 $\beta$ -Irradiation of Primary and Recurrent Pterygia with No Prior Surgical Excision. <i>Strahlentherapie Und Onkologie</i> , 2009, 185, 808-814.	1.0	12
92	Use of Gold Markers for Setup in Image-Guided Fractionated High-Dose-Rate Brachytherapy as a Monotherapy for Prostate Cancer. <i>Strahlentherapie Und Onkologie</i> , 2009, 185, 731-735.	1.0	12
93	Macro Monte Carlo for dose calculation of proton beams. <i>Physics in Medicine and Biology</i> , 2013, 58, 2027-2044.	1.6	12
94	Portfolio of prospective clinical trials including brachytherapy: an analysis of the ClinicalTrials.gov database. <i>Radiation Oncology</i> , 2016, 11, 48.	1.2	12
95	Single early palliative care intervention added to usual oncology care for patients with advanced cancer: A randomized controlled trial (SENS Trial). <i>Palliative Medicine</i> , 2021, 35, 1108-1117.	1.3	12
96	Prostate Radiotherapy for Men with Metastatic Disease: A New Comparison in the STAMPEDE Trial. <i>Clinical Oncology</i> , 2013, 25, 318-320.	0.6	11
97	Clinical Perspectives from Randomized Phase 3 Trials on Prostate Cancer: An Analysis of the ClinicalTrials.gov Database. <i>European Urology Focus</i> , 2015, 1, 173-184.	1.6	11
98	Radiotherapy in nodal oligorecurrent prostate cancer. <i>Strahlentherapie Und Onkologie</i> , 2021, 197, 575-580.	1.0	11
99	The predictive value of segmentation metrics on dosimetry in organs at risk of the brain. <i>Medical Image Analysis</i> , 2021, 73, 102161.	7.0	11
100	Noninvasive referencing of intraocular tumors for external beam radiation therapy using optical coherence tomography: A proof of concept. <i>Medical Physics</i> , 2014, 41, 081704.	1.6	10
101	A cost-effectiveness analysis of consolidative local therapy in oligometastatic non-squamous non-small cell lung cancer (NSCLC). <i>Radiotherapy and Oncology</i> , 2018, 129, 257-263.	0.3	10
102	Targeting the MET Receptor Tyrosine Kinase as a Strategy for Radiosensitization in Locoregionally Advanced Head and Neck Squamous Cell Carcinoma. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 614-626.	1.9	10
103	Dose-intensified versus conventional dose-salvage radiotherapy for biochemically recurrent prostate cancer after prostatectomy: Six-year outcomes of the SAKK 09/10 randomized phase III trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 194-194.	0.8	10
104	Treatment strategies to prevent and reduce gynecomastia and/or breast pain caused by antiandrogen therapy for prostate cancer. <i>Strahlentherapie Und Onkologie</i> , 2020, 196, 589-597.	1.0	10
105	Tailored total lymphoid irradiation in heart transplant patients: 10-years experience of one center. <i>Radiation Oncology</i> , 2010, 5, 3.	1.2	9
106	Impact of p53 Status on Radiosensitization of Tumor Cells by MET Inhibition—Associated Checkpoint Abrogation. <i>Molecular Cancer Research</i> , 2015, 13, 1544-1553.	1.5	9
107	Pattern of failure after adjuvant radiotherapy following extrapleural pneumonectomy of pleural mesothelioma in the SAKK 17/04 trial. <i>Radiotherapy and Oncology</i> , 2019, 138, 121-125.	0.3	9
108	Unplanned hospitalizations in patients with locoregionally advanced head and neck cancer treated with (chemo)radiotherapy with and without prophylactic percutaneous endoscopic gastrostomy. <i>Radiation Oncology</i> , 2020, 15, 281.	1.2	9

#	ARTICLE	IF	CITATIONS
109	The impact of delivery daytime and seasonality of radiotherapy for head and neck cancer on toxicity burden. <i>Radiotherapy and Oncology</i> , 2021, 158, 162-166.	0.3	9
110	Compensability index for compensation radiotherapy after treatment interruptions. <i>Radiation Oncology</i> , 2012, 7, 208.	1.2	8
111	Profiling Invasiveness in Head and Neck Cancer: Recent Contributions of Genomic and Transcriptomic Approaches. <i>Cancers</i> , 2015, 7, 585-597.	1.7	8
112	Definitive intensity modulated radiotherapy in locally advanced hypopharyngeal and laryngeal squamous cell carcinoma: mature treatment results and patterns of locoregional failure. <i>Radiation Oncology</i> , 2015, 10, 20.	1.2	8
113	External beam radiotherapy for unresectable hepatocellular carcinoma, an international multicenter phase I trial, SAKK 77/07 and SASL 26. <i>Radiation Oncology</i> , 2017, 12, 12.	1.2	8
114	Highly conformal combined radiotherapy with cisplatin and gemcitabine for treatment of loco-regionally advanced cervical cancer – a retrospective study. <i>Radiation Oncology</i> , 2017, 12, 202.	1.2	8
115	Synergistic effect of the TLR5 agonist CBLB502 and its downstream effector IL-22 against liver injury. <i>Cell Death and Disease</i> , 2021, 12, 366.	2.7	8
116	ProtRank: bypassing the imputation of missing values in differential expression analysis of proteomic data. <i>BMC Bioinformatics</i> , 2019, 20, 563.	1.2	7
117	Influencing Factors on Radiotherapy Outcome in Stage I-II Glottic Larynx Cancer – A Multicenter Study. <i>Frontiers in Oncology</i> , 2019, 9, 932.	1.3	7
118	Incidence of second primary cancers after radiotherapy combined with platinum and/or cetuximab in head and neck cancer patients. <i>Strahlentherapie Und Onkologie</i> , 2019, 195, 468-474.	1.0	7
119	Deciphering MET-dependent modulation of global cellular responses to DNA damage by quantitative phosphoproteomics. <i>Molecular Oncology</i> , 2020, 14, 1185-1206.	2.1	7
120	A new mouse model of radiation-induced liver disease reveals mitochondrial dysfunction as an underlying fibrotic stimulus. <i>JHEP Reports</i> , 2022, 4, 100508.	2.6	7
121	Potential and future strategies for radiotherapy in hepatocellular carcinoma. <i>Liver International</i> , 2009, 29, 145-146.	1.9	6
122	Postoperative Radiotherapy after Radical Prostatectomy: Indications and Open Questions. <i>Prostate Cancer</i> , 2012, 2012, 1-8.	0.4	6
123	Independent Monte-Carlo dose calculation for MLC based CyberKnife radiotherapy. <i>Physics in Medicine and Biology</i> , 2018, 63, 015015.	1.6	6
124	Vestibular dose correlates with dizziness after radiosurgery for the treatment of vestibular schwannoma. <i>Radiation Oncology</i> , 2021, 16, 61.	1.2	6
125	Treatment compliance and early toxicity in SAKK 01/10: Single-dose carboplatin and involved-node radiotherapy for treatment of stage IIA/B seminoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, 405-405.	0.8	6
126	Intensity-Modulated Radiotherapy for a Rendu-Osler-Weber Disease Patient with Recurrent Severe Epistaxis: A Case Report. <i>Case Reports in Medicine</i> , 2010, 2010, 1-4.	0.3	5



#	ARTICLE	IF	CITATIONS
127	Improved VMAT planning for head and neck tumors with an advanced optimization algorithm. Zeitschrift Fur Medizinische Physik, 2015, 25, 333-340.	0.6	5
128	Impact of regular magnetic resonance imaging follow-up after stereotactic radiotherapy to the surgical cavity in patients with one to three brain metastases. Radiation Oncology, 2019, 14, 45.	1.2	5
129	Impact of MET targeting on tumor-associated angiogenesis and growth of MET mutations-driven models of liver cancer. Genes and Cancer, 2015, 6, 317-327.	0.6	5
130	Matrix metalloproteinase-19 is a predictive marker for tumor invasiveness in patients with oropharyngeal squamous cell carcinoma. International Journal of Biological Markers, 2007, 22, 265-273.	0.7	5
131	Adherence to Contouring and Treatment Planning Requirements Within a Multicentric Trial: Results of the Quality Assurance of the SAKK 09/10 trial. International Journal of Radiation Oncology Biology Physics, 2022, 113, 80-91.	0.4	5
132	A hybrid column generation and simulated annealing algorithm for direct aperture optimization. Physics in Medicine and Biology, 2022, 67, 075003.	1.6	5
133	Re: Andrew J. Stephenson, Michel Bolla, Alberto Briganti, et al. Postoperative Radiation Therapy for Pathologically Advanced Prostate Cancer After Radical Prostatectomy. Eur Urol 2012;61:443-451. European Urology, 2012, 61, e39.	0.9	4
134	Assessing dose rate distributions in VMAT plans. Physics in Medicine and Biology, 2016, 61, 3208-3221.	1.6	4
135	Radiation Therapy Versus Radical Prostatectomy: A Never-ending Discussion. European Urology, 2016, 70, 31-32.	0.9	4
136	Adaptive step size algorithm to increase efficiency of proton macro Monte Carlo dose calculation. Radiation Oncology, 2019, 14, 165.	1.2	4
137	The prognostic impact of daytime and seasonality of radiotherapy on head and neck cancer. Radiotherapy and Oncology, 2021, 158, 293-299.	0.3	4
138	Response assessment after stereotactic body radiation therapy for spine and non-spine bone metastases: results from a single institutional study. Radiation Oncology, 2022, 17, 37.	1.2	4
139	Prevention of radiochemotherapy-induced toxicity with amifostine in patients with malignant orbital tumors involving the lacrimal gland: a pilot study. Radiation Oncology, 2008, 3, 22.	1.2	3
140	Role of Dose Intensification for Salvage Radiation Therapy after Radical Prostatectomy. Frontiers in Oncology, 2016, 6, 48.	1.3	3
141	Primary tumor volume delineation in head and neck cancer: missing the tip of the iceberg?. Radiation Oncology, 2017, 12, 102.	1.2	3
142	Biomechanical Modeling of Pterygium Radiation Surgery: A Retrospective Case Study. Sensors, 2017, 17, 1200.	2.1	3
143	Comparison of contemporary staging systems for oropharynx cancer in a surgically treated multi-institutional cohort. Head and Neck, 2019, 41, 1395-1402.	0.9	3
144	Validation of the decipher genomic classifier (GC) in SAKK 09/10: A phase III randomized trial of dose-escalated salvage radiotherapy (SRT) after radical prostatectomy (RP).. Journal of Clinical Oncology, 2021, 39, 5010-5010.	0.8	3

#	ARTICLE	IF	CITATIONS
145	Moderately hypofractionated radiotherapy as definitive treatment for localized prostate cancer: Pattern of practice in German-speaking countries. <i>Strahlentherapie Und Onkologie</i> , 2021, 197, 993-1000.	1.0	3
146	Feasibility of postoperative spine stereotactic body radiation therapy in proximity of carbon and titanium hybrid implants using a robotic radiotherapy device. <i>Radiation Oncology</i> , 2022, 17, 94.	1.2	3
147	A mathematical approach to human pterygium shape. <i>Clinical Ophthalmology</i> , 2016, Volume 10, 1343-1349.	0.9	2
148	Metabolomics reveals tepotinib-related mitochondrial dysfunction in <i>MET</i> -activating mutations-driven models. <i>FEBS Journal</i> , 2019, 286, 2692-2710.	2.2	2
149	Dose analysis of InCise 2 multi leaf collimator and IRIS-based stereotactic radiotherapy plans for brain and liver tumors. <i>Biomedical Physics and Engineering Express</i> , 2019, 5, 035007.	0.6	2
150	Impact of pretreatment second look 18FDG-PET/CT on stage and treatment changes in head and neck cancer. <i>Clinical and Translational Radiation Oncology</i> , 2021, 31, 8-13.	0.9	2
151	Human papillomavirus positive squamous cell carcinoma of the oropharynx. , 2001, 92, 805.		2
152	Acute toxicity and early quality of life after dose intensified salvage radiotherapy for biochemically recurrent prostate cancer after prostatectomy: First results of the randomized trial SAKK 09/10.. <i>Journal of Clinical Oncology</i> , 2015, 33, 5038-5038.	0.8	2
153	Development of a Monte Carlo based robustness calculation and evaluation tool. <i>Medical Physics</i> , 2022, 49, 4780-4793.	1.6	2
154	CECOG experts™ recommendations on the use of denosumab in the prevention of skeletal-related events in bone metastases of lung cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2013, 6, 75-82.	0.3	1
155	Physical examination during chemoradiation predicts outcome of locally advanced head and neck cancer. Secondary results of a randomized phase III trial (SAKK 10/94). <i>Oral Oncology</i> , 2013, 49, 1006-1009.	0.8	1
156	A Rare Case of a Large Spinal Meningioma with Mediastinal Extension and Malignant Behavior Classified Histologically as Benign. <i>Recent Results in Cancer Research</i> , 2013, 194, 443-455.	1.8	1
157	In Regard to Pisansky et Al. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 438-439.	0.4	1
158	Altered regulation of ERK1b by MEK1 and PTP-SL and modified Elk1 phosphorylation by ERK1b are caused by abrogation of the regulatory C-terminal sequence of ERKs.. <i>Journal of Biological Chemistry</i> , 2017, 292, 8852.	1.6	1
159	Is Dose-Intensified Salvage Radiation Therapy After Prostatectomy Beneficial?. <i>Journal of Clinical Oncology</i> , 2017, 35, 1490-1491.	0.8	1
160	A dosimetric evaluation of different levels of energy and intensity modulation for inversely planned multi-field MERT. <i>Biomedical Physics and Engineering Express</i> , 2018, 4, 045003.	0.6	1
161	Changes of Corneal Biomechanical Properties upon Exclusive Ytt-/Sr-90 Irradiation of Pterygium. <i>Sensors</i> , 2021, 21, 975.	2.1	1
162	SAKK 08/15-promet: Multicenter, randomized phase II trial of salvage radiotherapy +/- metformin for patients with prostate cancer after prostatectomy.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS157-TPS157.	0.8	1

#	ARTICLE	IF	CITATIONS
163	Organ-at-risk sparing with dynamic trajectory radiotherapy for head and neck cancer: comparison with volumetric arc therapy on a publicly available library of cases. Radiation Oncology, 2022, 17, .	1.2	1
164	In Response to Dr. Lacout etÂal.. International Journal of Radiation Oncology Biology Physics, 2011, 80, 962.	0.4	0
165	Reply to C. Cozzarini et al. Journal of Clinical Oncology, 2016, 34, 1705-1706.	0.8	0
166	Bladder-Preserving Combined-Modality Therapy: What Is Coming Next? A Critical Analysis of Phase 2-3 Trials of the ClinicalTrials.gov Database. International Journal of Radiation Oncology Biology Physics, 2016, 96, E283.	0.4	0
167	GERM-09. WHOLE VENTRICULAR IRRADIATION FOR INTRACRANIAL GERM CELL TUMORS: DOSIMETRIC COMPARISON OF PENCIL BEAM SCANNED PROTONS VS. IMRT. Neuro-Oncology, 2018, 20, i85-i85.	0.6	0
168	Skin surface markers for stereotactic body radiation therapy of sternal metastasis. Reports of Practical Oncology and Radiotherapy, 2019, 24, 322-324.	0.3	0
169	In Regard to Qi etÂal. International Journal of Radiation Oncology Biology Physics, 2020, 107, 224-225.	0.4	0
170	Abstract PO-026: DNA damage response and repair characterization in CHK2-deficient cancers. , 2021, , .		0
171	Abstract PO-039: Radiation therapy enhances anti-tumor activity of a MET CAR T-based immunotherapy approach for glioblastoma multiforme. , 2021, , .		0
172	Toward Data-Driven Radiation Oncology Using Standardized Terminology as a Starting Point: Cross-sectional Study. JMIR Formative Research, 2022, 6, e27550.	0.7	0
173	Abstract 1786: Characterization of the inhibitory capacity of EMD1214063, a novel small molecule inhibitor of the MET hepatocyte growth factor receptor on a panel of MET mutated variants. , 2012, , .		0
174	Abstract 1909: Cytoprotective autophagy is involved in resistance towards MET inhibitors in human gastric adenocarcinoma cells. , 2012, , .		0
175	Abstract C218: Relevance of p53 status for the response of tumor cells to MET inhibitors combined with irradiation.. , 2013, , .		0
176	THâ€ABâ€BRBâ€05: Quantification and Visualization of Treatment Plan Robustness in Radiotherapy. Medical Physics, 2015, 42, 3705-3705.	1.6	0